Lymphoproliferative disorders in kidney transplant recipients: Incidence, clinical characteristics and outcome;Syndromes lymphoprolifératifs après transplantation rénale : incidence et particularités cliniques et évolutives

Revue de Medecine Interne

Volumn 29, Issue 7, 2008, Pages 535-540

  Abderrahim, E ^a   Harzallah, A ^a   Barbouch, S ^a   Turki, S ^a   Helal, I ^a   Ben Abdallah, T ^a   Hedri, H ^a   Ben Moussa, F ^a   Bardi, R ^a   Ayed, K ^a   Ben Maiz H ^a   Kheder, A ^a  

^a CHARLES NICOLLE HOSPITAL   (Tunisia)

Author keywords

Kidney failure; Kidney transplantation; Lymphoma; Post transplant lymphoproliferative disease

Indexed keywords

AZATHIOPRINE; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DOXORUBICIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; CANCER RADIOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE DURATION; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INCIDENCE; KIDNEY GRAFT; LIVING DONOR; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TUNISIA;

EID: 45849121401     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2007.12.009     Document Type: Article

References (29)

1. Kasiske B.L., Snyder J.J., Gilbertson D.T., and Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 4 (2004) 905-913
2. Kauffman H.M., Cherikh W.S., McBride M.A., Cheng Y., and Hanto D.W. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transplant Int 19 (2006) 607-620
3. Euvrard S., Kanitakis J., and Claudy A. Skin cancers after organ transplantation. N Engl J Med 348 (2003) 1681-1691
4. Smith J.M., Rudser K., Gillen D., Kestenbaum B., Seliger S., Weiss N., et al. Risk of lymphoma after renal transplantation varies with time: an analysis of the United States renal data system. Transplantation 81 (2006) 175-180
5. Caillard S., Lelong C., Pessione F., Moulin B., and French PTLD Working Group. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French registry. Am J Transplant 6 (2006) 2735-2742
6. Bates W.D., Gray D.W., Dada M.A., Chetty R., Gatter K.C., Davies D.R., et al. Lymphoproliferative disorders in Oxford renal transplant recipients. J Clin Pathol 56 (2003) 439-446
7. Opelz G., and Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4 (2004) 222-230
8. Jougla E. Tests statistiques relatifs aux indicateurs de mortalité en population. Rev Epidemiol Sante Publique 45 (1997) 78-84
9. Cherikh W.S., Kauffman H.M., McBride M.A., Maghirang J., Swinnen L.J., and Hanto D.W. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 76 (2003) 1289-1293
10. Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G., O'Sullivan E.J., Johnson M.R., Heroux A.L., et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 323 (1990) 723-728
11. Le Meur Y., Potelune N., Jaccard A., Petit B., Bordessoule D., Peyronnet P., et al. Syndromes lymphoprolifératifs après transplantation rénale. Nephrologie 19 (1998) 255-261
12. Dharnidharka V.R., Tejani A.H., Ho P.L., and Harmon W.E. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant 2 (2002) 993-998
13. Jain M., Badwal S., Pandey R., Srivastava A., Sharma R.K., and Gupta R.K. Post-transplant lymphoproliferative disorders after live donor renal transplantation. Clin Transplant 19 (2005) 668-673
14. Babel N., Vergopoulos A., Trappe R.U., Oertel S., Hammer M.H., Karaivanov S., et al. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation 84 (2007) 387-391
15. Bakker N.A., van Imhoff G.W., Verschuuren E.A., van Son W.J., van der Heide J.J., Lems S.P., et al. HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation 80 (2005) 595-599
16. Funch D.P., Walker A.M., Schneider G., Ziyadeh N.J., and Pescovitz M.D. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 5 (2005) 2894-2900
17. Lim W.H., Russ G.R., and Coates P.T. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation. Nephrology 11 (2006) 355-366
18. Young L., Alfieri C., Hennessy K., Evans H., O'Hara C., Anderson K.C., et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321 (1989) 1080-1085
19. Buda A., Caforio A., Calabrese F., Fagiuoli S., Pevere S., Livi U., et al. Lymphoproliferative disorders in heart transplant recipients: role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection. Transpl Int 13 Suppl. 1 (2000) 402-405
20. Walker R.C., Marshall W.F., Strickler J.G., Wiesner R.H., Velosa J.A., Habermann T.M., et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 20 (1995) 1346-1353
21. Kapelushnik J., Ariad S., Benharroch D., Landau D., Moser A., Delsol G., et al. Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi's sarcoma. Br J Haematol 113 (2001) 425-428
22. Tsai D.E., Hardy C.L., Tomaszewski J.E., Kotloff R.M., Oltoff K.M., Somer B.G., et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71 (2001) 1076-1088
23. Mentzer S.J., Perrine S.P., and Faller D.V. Epstein-Barr virus post transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis 3 (2001) 177-185
24. Oertel S.H., Verschuuren E., Reinke P., Zeidler K., Papp-Vary M., Babel N., et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5 (2005) 2901-2906
25. Choquet S., Trappe R., Leblond V., Jager U., Davi F., and Oertel S. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 92 (2007) 273-274
26. Davis C.L. Interferon and cytotoxic chemotherapy for the treatment of post transplant lymphoproliferative disorder. Transpl Infect Dis 3 (2001) 108-118
27. Cullis B., D'Souza R., McCullagh P., Harries S., Nicholls A., Lee R., et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 47 (2006) E67-E72
28. Campistol J.M., Gutierrez-Dalmau A., and Torregrosa J.V. Conversion to Sirolimus: A successful Treatment for posttransplantation Kaposis's sarcoma. Transplantation 77 (2004) 760-762
29. Johnson S.R., Cherikh W.S., Kauffman H.M., Pavlakis M., and Hanto D.W. Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis. Am J Transplant 6 (2006) 2743-2749